EP2114475A2 - Dispositif à effet biologique et procédé de fabrication de celui-ci - Google Patents

Dispositif à effet biologique et procédé de fabrication de celui-ci

Info

Publication number
EP2114475A2
EP2114475A2 EP08707489A EP08707489A EP2114475A2 EP 2114475 A2 EP2114475 A2 EP 2114475A2 EP 08707489 A EP08707489 A EP 08707489A EP 08707489 A EP08707489 A EP 08707489A EP 2114475 A2 EP2114475 A2 EP 2114475A2
Authority
EP
European Patent Office
Prior art keywords
nanoparticles
base body
substance
implant
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08707489A
Other languages
German (de)
English (en)
Inventor
Stephan Barcikowski
Thomas Lenarz
Timo STÖVER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LZH Laser Zentrum Hannover eV
Original Assignee
LZH Laser Zentrum Hannover eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LZH Laser Zentrum Hannover eV filed Critical LZH Laser Zentrum Hannover eV
Publication of EP2114475A2 publication Critical patent/EP2114475A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/446—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L31/128—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/10—Metallic powder containing lubricating or binding agents; Metallic powder containing organic material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F3/00—Manufacture of workpieces or articles from metallic powder characterised by the manner of compacting or sintering; Apparatus specially adapted therefor ; Presses and furnaces
    • B22F3/22—Manufacture of workpieces or articles from metallic powder characterised by the manner of compacting or sintering; Apparatus specially adapted therefor ; Presses and furnaces for producing castings from a slip
    • B22F3/225—Manufacture of workpieces or articles from metallic powder characterised by the manner of compacting or sintering; Apparatus specially adapted therefor ; Presses and furnaces for producing castings from a slip by injection molding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/624—Nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces

Definitions

  • the present invention relates to a biologically active device and a method for its preparation.
  • a biologically-effective device is meant a device capable of acting on or interacting with a surrounding biological material, a special case of such a biologically-active device being medical devices, apparatus and instruments ,
  • a particular example of a biologically active device is an implant that is introduced into a human or animal body.
  • an implant When inserting an implant into the body of a patient, there is often a risk of bacteria accumulating on the implant, causing an immune reaction and causing inflammation of the tissue in which the implant is embedded.
  • Another problem may be that implantation causes increased connective tissue growth.
  • the new connective tissue cells overlay the implant, making it more difficult to deliver electrical or optical signals from the implant (such as cardiac pacemakers, cochlear or neuro-implants) to nerve cells in the vicinity of the implant.
  • a solid main body of an implant with a surface coating in or on which anti-microbial, anti-bacterial or anti-proliferative (i.e., cell growth inhibiting) substances are arranged.
  • DE 197 56790 A1 proposes to incorporate anti-microbial silver particles with a particle size of 20 nm into a polymer.
  • a fixed main body of an implant is provided with a double-layered coating.
  • An inner reservoir layer contains biocidal (ie cell damaging) active substances with a particle size below 50 nm.
  • the biocidal active substance can thereby Silver, copper or zinc.
  • An outer "transport control layer” serves to throttle the release of the drug.
  • EP 1 131 114 B1 proposes covering the surface of an implant with a polymer layer in which a tissue reaction modifier is incorporated.
  • US 2004/0215338 A1 relates to a coated stent graft.
  • a coating of the stent graft base contains bioactive nanoparticles that release exclusively antiproliferative substances.
  • WO 2006/096791 A1 describes an implant which serves as a "framework" for tissue regeneration
  • the basic body of the implant consists of polymer nanofibers on which there are nanoparticles which release bioactive molecules.
  • WO 2006/068838 A2 discloses medical implants with a nanoporous or "nano-textured” surface in which no nanoparticles but cell adhesion-promoting biomolecules can be embedded.
  • WO 2003/049795 A2 describes several possibilities for the production of implants, in which a "nanoparticulate filier" is integrated into a matrix
  • US 2006/0177379 A1 discloses a material for implants which contains (for example in the form of nanoparticles) both a “therapeutically active agent” and a “signal-generating agent” which are released together into the environment. Based on physical or chemical measurements of the signal-generating agent (e.g., by X-ray or spectroscopy), the delivery of the therapeutic can be monitored.
  • US 2005/0095267 A1 proposes a nanoparticle-containing polymer coating for implants. However, it refers exclusively to nanoparticles that release anti-proliferative substances.
  • US 2006/0188543 A1 deals with cardiovascular stents with a Li-ion monolayer coating which comprises nanoparticles of a biodegradable and / or biurable contains sorbable polymer, which in turn carry an active ingredient. Since the goal is to prevent vascular restenosis, only anti-proliferative agents are used.
  • the object of the present invention is to provide a biologically effective device which is relatively easy to manufacture and can be easily adapted to different environments or requirements and can interact ideally with surrounding, biological material.
  • nanoparticles which release substances interacting with biological receptors in their environment
  • nanoparticles means that these particles have a dimension in the sub-micron range.
  • Such nanoparticles by virtue of their small size, have a comparatively large surface area over which they can expose active substances [in the case of metallic nanoparticles, for example. Can give ions).
  • active substances in the case of metallic nanoparticles, for example.
  • Can give ions At the same time, in contrast to simple molecules, they also represent a considerable reservoir for the substances to be delivered on the basis of their volume.
  • the bioactive nanoparticles are not arranged exclusively in a 3-layer of a basic body, but they are embedded in the basic body itself, wherein the basic body is formed from a polymer. This allows a very simple, compact construction of the biologically active device because the basic body of the device not only its shape, but also its bioactive function.
  • the biologically active device differs above all in that it comprises nanoparticles of different substances which have different, at the very least, even opposing effects on a biological material) of the tissue into which the device is embedded or with which the device ⁇ ontaktierbar is. While the nanoparticles of a substance release a substance that exerts a droliferative effect, other nanoparticles release a substance that has an anti-proliferative or anti-3dherent effect on biological material in the environment of the device.
  • proliferative or “proliferation” is meant in connection with jer invention not only a beneficial effect on the cell or tissue growth, but any positive effect on the biological material surrounding the device, for example, a promotion of cell adhesion, ie the Attachment of the cells to the device.
  • anti-proliferative is understood to mean all adverse effects on zoological material, including anti-bacterial or anti-microbial agents, and an “anti-adherent” effect is that the attachment of biological material, including biofilms, to the device delayed, slowed down, obstructed or even completely prevented.
  • an implant should only be equipped with exclusively anti-sroliferative (eg, cell growth-braking) substances, since otherwise an unwanted, inflammation-inducing increase of germs would favors, or only with exclusively proliferative (eg cell growth promoting) substances, because otherwise the two opposing effects would cancel each other out.
  • anti-sroliferative eg, cell growth-braking
  • proliferative eg cell growth promoting
  • tissue eg endothelial cells: ibroblasten, or nerve cells
  • tissue type overgrowth e.g endothelial cells: ibroblasten, or nerve cells
  • the invention is based on investigations of the inventors, which suggest the suspicion that "proliferative" nanoparticles of certain substances or combinations of substances are apparently capable of selectively promoting the proliferation of specific cell types, while scarcely affecting the propagation of other cells (eg connective tissue) or germs It is also surprising that the combined presence of proliferative and anti-proliferative substances, for example, can considerably improve the ingrowth behavior and the long-term stability of an implant. proliferative substances prevent the unwanted attachment of certain cells, while the proliferative substances favor the desired encapsulation of the implant with other cell types by selecting a proliferative and Biner anti-prolife active substance can therefore be targeted to promote the proliferation of one cell type and the proliferation of another cell type can be slowed down or prevented.
  • the biologically effective device according to the invention can not only be used as an implant Dder for an implant. Rather, it is also conceivable to use them for cell differentiation in a mixed cell culture, for example for stem cell differentiation. If this is done in vitro, the device could be part of a Petri dish in which the viral culture is recorded.
  • suitable nanoparticles to act on certain biological materials eg, cell lines or cell types
  • the antiproliferative nanoparticles of a second substance could suppress the growth of other types of lycopene, further promoting selection.
  • the nanoparticles of the at least one proliferatively active substance are nanoparticles which release metallic or metal ions and which can exert proliferative action on specific tissue via the ablation of ions.
  • the proliferative nanoparticles could contain titanium, iron, magnesium and / or oxides of these metals. They could even be made of pure metal.
  • certain substances, such as iron, titanium or magnesium have a neurotrophic effect, ie specifically support the growth of nerve cells. This finding is valuable, for example, for implants in which an electrical or optical signal transmission from or to the nerves is to take place, for example in cochlear (inner ear) implants, brain implants or even cardiac pacemakers.
  • Such implants require the best possible contact between the nerve and an electrical (or optical) conductor in the implant. Frequently, pores are even provided in the implant, through which the nerve cells can spread to the electrical conductor. Disruptive effect, however, is when connective tissue cells grow faster than the nerve cells in the pores and thus "clogged.” With the device according to the invention, this problem can be prevented by the delivered by the device (s) substances favors the growth of the nerve cells and ensures that the nerve cells grow faster than the rest of the tissue to the device and in particular to an electrical conductor therein if necessary.
  • inorganic, proliferative nanoparticles can be provided in the main body of the device.
  • the polymer backbone can comprise proliferatively active nanoparticles of an organic material, a biological material (e.g., peptides), or a drug such that the device could serve for drug delivery.
  • the surface-volume ratio of the nanoparticles and their concentration in the polymer can be used to set their storage capacity and the rate at which substances in the nanoparticles the environment of the device are delivered.
  • An average size of 20 to 300 nm, preferably 60 to 200 nm has proven to be particularly advantageous. If the nanoparticles are even smaller, their storage capacity is too low.
  • nanoparticles that release anti-proliferative or anti-adherent substances for example, nanoparticles are the silver, zinc, cobalt, aluminum, copper and / or oxides of these metals, such as Co 2 O, CuO 1 ZnO, ZnCl 2 or CuCl 2
  • anti-proliferative nanoparticles of an organic or an inorganic substance such as an antibiotic or other drugs
  • any polymer could be used as the material for the basic body.
  • the polymer base body comprises silicone, since silicone has proved to be a particularly good material for implants with regard to its biocompatibility and its ability to store nanoparticles moreover, that the Polymermate ⁇ al provides the substances released from the nanoparticles the ability to get to the surface of the device and from there into the environment of the device Also in this regard, silicone is excellent
  • the polymer body is provided at least in sections with at least one coating.
  • This coating can serve to control or brake the release of the bioactive substance (s) from the body by arranging the coating (only) on certain areas
  • the delivery of bioactive substance from the device can be varied locally
  • nanoparticles of one or more substances are embedded in the coating. This enables a two-stage effect of the device to be achieved.
  • the delivery of a bioactive substance from the basic body can take place at a different rate (usually slower) than the delivery of a substance from the coating because a further way to the surface has to be covered from the basic body
  • the coating has a barrier effect (ie it locally slows down or prevents the escape of substances from the device, or it prevents the unwanted ingress of substances from the environment into the device), has a biological function or acts biomimetic latter may mean, for example, that the coating has a surface finish or a surface roughness. which is preferred by certain cell types and further supports the proliferative effect of the substance released from the device.
  • the coating does not necessarily have to be single-layered, but it could also comprise several layers, each of which may have different functions. For example, nanoparticles of different materials could be embedded in each layer.
  • the device is an implant (or part of a graft), preferably with a signal transmitting device for electrical signal transmission to or from the surrounding tissue, e.g. a cochlear implant.
  • a signal transmitting device for electrical signal transmission e.g. a cochlear implant.
  • an electrical conductor could be present, which for reasons of biocompatibility can be formed from platinum-iridium or another noble metal.
  • the signal transmission between the conductor in the implant and the nerve cells in the surrounding tissue can be significantly improved if the proliferation of the nerve cells on the implant is preferred and the nerve cells grow on or near the conductor before the space between them fills the nerve and the conductor with other biological material, thus increasing the impedance in signal transmission.
  • the device as or for a cardio / acicular implant, in particular a heart valve, a polymer stent or a prosthetic socket.
  • a cardio / acicular implant in particular a heart valve, a polymer stent or a prosthetic socket.
  • intimal hyperplasia in which the implant is overgrown in a short time by SMC cells (smooth muscle cells, plate muscle cells).
  • SMC cells smooth muscle cells, plate muscle cells.
  • the device according to the invention can selectively promote the growth or proliferation of endothelial cells by setting a specific magnesium concentration n in the environment of the device without promoting the proliferation of the SMC cells.
  • cell selection or cell differentiation takes place, being preferred in endothelial cells.
  • the implant could also be a temporary body-worn port catheter, a microstent for ophthalmology, or a ureteral stent urinary stent).
  • arcon PES material for cardiovascular implants, this has been found available under the trade name) arcon PES material as appropriate.
  • polymer material must in the present invention, no pure material can be used, but in the Polymermate ⁇ al other additives could be present, such as carbon fibers or other fibers to improve the mechanical properties
  • the device could also be a catheter, a port catheter not remaining as an implant in the body, a tracheostomy tube or a tracheostomy tube, or a portion of these products
  • the present invention also consists in a method for producing a biologically active device. Firstly, nanoparticles of a plurality of different substances are produced and dispersed in a moldable liquid before the liquid is injection molded and cured to form a polymer body of the device, such that the nanoparticles In particular, the nanoparticles could be homogeneously distributed in the basic body. According to the invention, the nanoparticles are produced by arranging at least two substrates of different material in a sample vessel filled with liquid material (eg a monomer or solvent) and the nanoparticles are produced by ablating the surface of the substrates in the liquid by laser beam deposition (eg by means of pulsed laser radiation)
  • liquid material eg a monomer or solvent
  • the device can be produced comparatively easily because the basic body determines both the shape of the device and its biological effect.
  • the device is characterized by the selection of the material and the size of the nanoparticles and by the selection of a nanoparticle Polymers perfectly adaptable to different applications It has also been shown that by adjusting the laser parameters (pulse duration, wavelength, fluence, etc.), the shape and size of the nanoparticles generated from the substrate can be set in a targeted manner
  • the essential advantage of the process according to the invention is that two or more colloids of different substances need not be prepared separately and then mixed, which can enhance a number of problems, including an increase in volume, inadequate, inhomogeneous mixing, or a possible coalescence.
  • Precipitation fragmentation of one of the two or both types of nanoparticles
  • the nanoparticles of different materials are instead bound in one and the same vessel generated, possibly even simultaneously or intermittently.
  • the interaction of the laser radiation of the two or more native (ie freshly generated) nanoparticle types with the laser radiation leads to unexpected advantages over subsequent mixing; It has been shown, for example, that one type of particle (eg, plasmone-specific) can transfer absorbed energy to the other, so that the second variety becomes smaller and / or more stable than if it had been generated separately. It has also been shown that the native nanoparticles are more reactive than at later points in time, so that they can be combined (eg sorbed or alloyed) in a controlled manner with particles also freshly produced in the same vessel. The colloidal stability is retained (lower flocculation or agglomeration or Sedimentationsne Trent). In addition, eliminates the problems that would otherwise arise when mixing different colloids.
  • one type of particle eg, plasmone-specific
  • the native nanoparticles are more reactive than at later points in time, so that they can be combined (eg sorbed or alloyed) in a controlled manner with particles also freshly produced in the same vessel.
  • the nanoparticles of at least one substance can preferably be proliferatively active when the device is embedded in a tissue.
  • the device contains nanoparticles of at least one when embedding the device in a tissue anti-proliferative or anti-adherent active substance, possibly even in combination with nanoparticles of another, proliferatively active substance.
  • the generation of the nanoparticles by ablation of the surface of a substrate by means of a short-pulse or ultrashort-pulse laser, i. with pulse durations in the nanosecond (ns), picosecond (ps) or femtosecond (fs) range.
  • a short-pulse or ultrashort-pulse laser i. with pulse durations in the nanosecond (ns), picosecond (ps) or femtosecond (fs) range.
  • the nanoparticles can be stoichiometrically recovered from the substrate, because due to the shortness of the pulses, a thermal effect on the substrate is omitted.
  • a thermal influence on the liquid surrounding the substrate is avoided.
  • the removal can be carried out alternately from the two or more substrates.
  • the laser may be passed over the substrates in random order or repeatedly in a predetermined order. In this way, the nanoparticles of different substances are produced almost simultaneously, resulting in an excellent mixing.
  • each laser pulse can be guided onto a different substrate than the laser pulse that is being generated
  • the laser pulses or radiation are aligned by a controllable Ablenk- Bin ⁇ chtung with one or two deflectable mirrors on the different substrates, such as a galvanometric scanner
  • the liquid material in which the nanoparticles are produced could itself be a liquid capable of casting (a monomer solution) or, after the nanoparticles have been produced, be replaced by a liquid which can be injection-molded
  • the invention is characterized in that it provides a Sp ⁇ tzguss-Sch ⁇ tt
  • the injection molding has the advantage of simultaneously producing a variety of similar or distinguished I-shaped polymer main body This method reduces the costs for the manufacture of the devices considerably
  • the polymer body can be provided with a coating on at least a portion of its surface in order to control the release of substances from the body or to make it difficult to dispense further substances stored in the coating
  • FIG. 2A shows a schematic representation of the generation of the nanoparticles
  • FIG. 2B shows a schematic representation of the injection molding of the invention.
  • ⁇ gur 1 shows a section through an exemplary embodiment of an inventive bio- jisch effective device 1 of the base body 2 may be, It comprises a polymer base body 2, which is injection molded vorzugswei- »e of silicone or Darcon B plattenformig or be cylindrically shaped and depending on the application have a height extent H of about 1 mm to several centimeters.
  • Bioactive nanoparticles 3 of different substances having a size of 60 to 200 nm are homogeneously dispersed in the volume of the base body 2.
  • the nanoparticles 3 release a substance that diffuses out of the device 1 and onto biological material (not shown) over its surface. in the vicinity of the device 1 "bioactive" acts. While the nanoparticles 3 of a substance emit a substance which acts proliferatively on the biological material, the nanoparticles 3 of another substance emit a substance which has an anti-proliferative or anti-adherent effect.
  • the nanoparticles 3 of a type of calcium, calcium salt, calcium phosphate, hydroxyapatite, magnesium, magnesium salt or titanium could consist of titanium oxide and release calcium-magnesium or titanium ions, which have a positive effect, in particular on nerve cells, i. could be neurotrophic.
  • Nanoparticles 3 made of silver or copper or zinc (oxide), which are likewise dispersed in the main body 2, could be present as anti-proliferative or anti-adherent nanoparticles.
  • a conductor 4 is embedded, e.g. inserted. It serves to deliver electrical (or optical) signals to the biological environment of the device 1 or to receive electrical (or optical) signals therefrom.
  • a cochlear implant e.g. Signals are sent to the auditory nerves.
  • the main body 2 has pores 5, on which the surface of the main body 2 is retracted so far that the electrical conductor 4 is exposed. He can be contacted directly by nerve cells. However, the prerequisite is that the nerve cells grow into the pores 5. This is achieved by virtue of the fact that at least one substance that exits the nanoparticles 3 has a selective proliferative effect on the nerve cells, so that their growth in the pores 5 is favored.
  • the substances released by the "anti-proliferative" nanoparticles can, for example, have an anti-proliferative effect on non-nerve cells and thus prevent other cells (eg connective tissue) from occupying the pores 5 earlier than the nerve cells.
  • the surface of the device 1 is provided with a coating 6, which, however, is recessed in the region of the pores 5.
  • the coating influences the escape of proliferative substances from the main body 2. Consequently, the concentration of these substances in the area of the pores 5 is particularly high, so that the nerve cells will preferentially grow in the direction of the pores 5 and into the pores. Accordingly, an anisotropic distribution of the bioactive substances) can be set outside of the device 1 via the respective arrangement of the coating 6.
  • the coating 6 may in turn contain bioactive nanoparticles 3, which may have a proliferative and / or anti-proliferative effect on certain tissue or cell types.
  • Fig. 2 shows a broad outline of a preferred variant of the manufacturing method according to the invention.
  • one or more (here: two) substrates 10 are received in a sample vessel 11 filled with a liquid material 12.
  • Each substrate 10 is a substance from which nanoparticles 3 are subsequently obtained.
  • the liquid material 12 can already be an injection-moldable liquid or a solvent which is later replaced in one or more steps by an injection-moldable liquid.
  • a beam 13 of an ultra-short pulse laser is focused on or near the surface of a substrate 10 via focusing optics 14.
  • the laser pulses expose nanoparticles 3 out of the substrate 10, which are immediately dispersed and stabilized in the liquid material 12. If a further substrate 10 of another material is present, nanoparticles can likewise be obtained by suitably deflecting the laser pulses from this further substrate 10.
  • the laser beam can be directed intermittently onto the two or more substrates, for example, so that the laser pulses are alternately set on the two substrates.
  • the liquid material 12, in which the nanoparticles 3 are dispersed is optionally replaced by an injection-moldable prepolymer liquid 15 (so that the nanoparticles are now dispersed in the injection-moldable liquid) and then taken up in a reservoir 16.
  • Fig. 2B shows that the injection-moldable liquid 15 from the reservoir 16 via a conduit 17 is passed to an injection molding nozzle 18 to be introduced through the nozzle 18 into the mold cavity 19 of a multi-part injection molding tool 20.
  • the injected liquid 15 cures to form a polymer base body 2, in the volume of which the nanoparticles 3 are now dispersed or embedded. If necessary, the base body 2 can be provided with a coating 6 after curing.
  • the resulting device 1 according to the invention can then be used, for example, as an implant, or in a cell culture for differentiating different cell types.
  • the device 1 and the method according to the invention can be modified in many ways, in particular with regard to the materials used in the process.
  • the mold could comprise a plurality of mold cavities in which a corresponding number of device according to the invention would be produced at the same time.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Materials Engineering (AREA)
  • Composite Materials (AREA)
  • Manufacturing & Machinery (AREA)
  • Mechanical Engineering (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Prostheses (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

L'invention concerne un dispositif à effet biologique (1) comportant un corps de base (2) constitué par un polymère, dans lequel des nanoparticules bioactives (3) d'une ou plusieurs substances sont intégrées. Les nanoparticules (3) d'au moins une substance ont un effet prolifératif sur un matériau biologique avec lequel le dispositif (1) peut être mis en contact, et des nanoparticules (3) d'une autre substance ont un effet anti-prolifératif sur le matériau biologique dans l'environnement du dispositif (1). L'invention concerne également un procédé de fabrication d'un dispositif à effet biologique (1) comportant un corps de base (2) constitué par un polymère. Selon ledit procédé, des nanoparticules (3) de plusieurs substances différentes sont dispersées dans un liquide (15) pouvant être moulé par injection, et le liquide est moulé sous la forme du corps de base polymère (2) par moulage par injection et durcissage, de telle manière que les nanoparticules (3) sont dispersées dans le volume du corps de base polymère (2). Selon l'invention, les nanoparticules (3) sont fabriquées par disposition d'au moins deux substrats (10) de matériaux différents dans une cuvette à échantillon (11) remplie de matériau liquide (12), et enlèvement des nanoparticules (3) de la surface des substrats (10) dans le liquide (12) au moyen de rayonnement laser (13).
EP08707489A 2007-02-06 2008-02-01 Dispositif à effet biologique et procédé de fabrication de celui-ci Withdrawn EP2114475A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007005817A DE102007005817A1 (de) 2007-02-06 2007-02-06 Biologisch wirksame Vorrichtung und Verfahren zu ihrer Herstellung
PCT/EP2008/000803 WO2008095645A2 (fr) 2007-02-06 2008-02-01 Dispositif à effet biologique et procédé de fabrication de celui-ci

Publications (1)

Publication Number Publication Date
EP2114475A2 true EP2114475A2 (fr) 2009-11-11

Family

ID=39597412

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08707489A Withdrawn EP2114475A2 (fr) 2007-02-06 2008-02-01 Dispositif à effet biologique et procédé de fabrication de celui-ci

Country Status (4)

Country Link
US (1) US20100291174A1 (fr)
EP (1) EP2114475A2 (fr)
DE (1) DE102007005817A1 (fr)
WO (1) WO2008095645A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008033570B4 (de) * 2008-07-15 2010-09-30 Masterrind Gmbh Verfahren zur Zellidentifikation und Zellsortierung
DE102009007667B4 (de) * 2009-02-05 2012-04-19 Raumedic Ag Medizinisches Arbeitsmittel sowie Verfahren und Vorrichtung zur Herstellung eines derartigen medizinischen Arbeitsmittels
DE102010018073A1 (de) 2010-04-20 2011-10-20 Aesculap Ag Copolymermodifizierte Nanopartikel, insbesondere zur Verwendung bei medizintechnischen Gegenständen
ITMI20120171A1 (it) 2012-02-08 2013-08-09 Alessio Gerardo Maugeri Impianti per fluidi comprendenti nanomateriali
EP2762226A1 (fr) * 2013-02-01 2014-08-06 Centre de Recherche Public Henri Tudor Revêtement hybride et procédé pour l'obtenir
GB2511528A (en) 2013-03-06 2014-09-10 Speciality Fibres And Materials Ltd Absorbent materials
DE102014101588B4 (de) * 2014-02-10 2022-06-02 Pac Tech-Packaging Technologies Gmbh Anordnung zum Aufbringen von leitenden Nanopartikeln auf ein Substrat
US10064273B2 (en) 2015-10-20 2018-08-28 MR Label Company Antimicrobial copper sheet overlays and related methods for making and using

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585020A (en) * 1994-11-03 1996-12-17 Becker; Michael F. Process for the production of nanoparticles
US6855749B1 (en) * 1996-09-03 2005-02-15 Nanoproducts Corporation Polymer nanocomposite implants with enhanced transparency and mechanical properties for administration within humans or animals
DE19756790A1 (de) 1997-12-19 1999-07-01 Fraunhofer Ges Forschung Prepolymer mit darin isoliert dispergierten nanoskaligen Feststoffteilchen, Verfahren zu seiner Herstellung und seine Verwendung
ATE269114T1 (de) 1998-11-20 2004-07-15 Univ Connecticut Verfahren und vorrichtung zur steuerung der gewebeimplantat-interaktionen
US7255881B2 (en) * 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
AU2002356530A1 (en) * 2001-09-28 2003-04-07 Boston Scientific Limited Medical devices comprising nanomaterials and therapeutic methods utilizing the same
US20030064965A1 (en) * 2001-10-02 2003-04-03 Jacob Richter Method of delivering drugs to a tissue using drug-coated medical devices
GB0127786D0 (en) * 2001-11-20 2002-01-09 Univ Nottingham Impregnation of antimicrobial substances
DE10243132B4 (de) 2002-09-17 2006-09-14 Biocer Entwicklungs Gmbh Antiinfektiöse, biokompatible Titanoxid-Beschichtungen für Implantate sowie Verfahren zu deren Herstellung
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
US6803070B2 (en) * 2002-12-30 2004-10-12 Scimed Life Systems, Inc. Apparatus and method for embedding nanoparticles in polymeric medical devices
US20060102871A1 (en) * 2003-04-08 2006-05-18 Xingwu Wang Novel composition
US20040215338A1 (en) * 2003-04-24 2004-10-28 Jeff Elkins Method and system for drug delivery to abdominal aortic or thoracic aortic aneurysms
KR100540887B1 (ko) * 2003-08-28 2006-01-11 학교법인단국대학 레이저 어블레이션에 의한 비구형 금-백금 바이메탈 나노입자
DE10353756A1 (de) 2003-11-17 2005-06-30 Bio-Gate Bioinnovative Materials Gmbh Schichtmaterial
EP3153159A1 (fr) * 2004-07-09 2017-04-12 Robert Sabin Compositions comprenant un composé de cuivre pour le traitement de maladies mammaliennes
US20060129215A1 (en) * 2004-12-09 2006-06-15 Helmus Michael N Medical devices having nanostructured regions for controlled tissue biocompatibility and drug delivery
EP1830902A2 (fr) * 2004-12-30 2007-09-12 Cinvention Ag Ensemble comprenant un agent produisant un signal, un implant et un medicament
US20060188543A1 (en) * 2005-01-31 2006-08-24 Si-Shen Feng Nanoparticle coating for drug delivery
JP2008536539A (ja) * 2005-03-07 2008-09-11 ジョージア テック リサーチ コーポレイション 組織再生のためのナノフィラメントの足場
WO2007003516A2 (fr) * 2005-07-01 2007-01-11 Cinvention Ag Dispositifs medicaux comprenant une matiere composite reticulee

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008095645A2 *

Also Published As

Publication number Publication date
WO2008095645A2 (fr) 2008-08-14
US20100291174A1 (en) 2010-11-18
DE102007005817A1 (de) 2008-08-14
WO2008095645A3 (fr) 2008-12-18

Similar Documents

Publication Publication Date Title
EP2114475A2 (fr) Dispositif à effet biologique et procédé de fabrication de celui-ci
EP0770401B1 (fr) Procédé de fabrication de stents intraluminaux en polymère biorésorbable
EP1701676B1 (fr) Pansement
EP2224970B1 (fr) Implant et procédé de revêtement d'un implant
DE102004062394B4 (de) Intravenöse Herzschrittmacherelektrode und Verfahren zu deren Herstellung
WO2018122418A1 (fr) Endoprothèse en alliage de magnésium biodégradable recouverte d'un revêtement en fluorure de magnésium et d'un revêtement organique
EP1513563A1 (fr) Implant a action longue duree antibiotique
EP1796750B1 (fr) Implant antimicrobien comprenant une structure poreuse souple dans un forme d'un tissu non tissé
EP2217296B1 (fr) Matériau de suture chirurgical
DE102005044360A1 (de) Antimikrobielles medizintechnisches Produkt, Verfahren zu seiner Herstellung und Verwendung
EP3432941B1 (fr) Corps d'implant comportant une couche porteuse d'agent actif et une couche de commande de libération
EP2185208B1 (fr) Implant mammaire à effet antibactérien
DE102010055561B4 (de) Beschichtungsverfahren und Beschichtungsvorrichtung
EP2701757B1 (fr) Tuteur vasculaire implantable
EP2617439B1 (fr) Revêtement d'implant antibactérien et ostéo-inducteur, procédé de fabrication d'un tel revêtement et implant revêtu ainsi
EP3946487A1 (fr) Implant doté d'une efficacité antimicrobienne intrinsèque et procédé de sa production
EP3613449A1 (fr) Amélioration de la couche polymère dans des dispositifs dégradables
WO2007118848A2 (fr) Procédé de production d'une structure biocompatible, en particulier d'un implant
WO2014063816A1 (fr) Implant percutané et procédé pour réaliser un tel implant
DE102006037497A1 (de) Poröser Festkörper mit bimodaler Porengrößenverteilung sowie Verfahren zu dessen Herstellung
DE102012213781B4 (de) Medizinische Hybridimplantate
EP3159017B1 (fr) Matrice resorbable destinee au recouvrement de plaie
WO2020021075A1 (fr) Système hybride comprenant des nanoparticules nanoporeuses dans une structure en métal précieux et procédé pour sa fabrication et son utilisation
EP4072606B1 (fr) Implant, composant d'implant et méthode pour leur production
WO2023057310A1 (fr) Corps solide biocorrodable et procédé de revêtement d'un corps solide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090716

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BARCIKOWSKI, STEPHAN, DR.

Inventor name: LENARZ, THOMAS

Inventor name: STOEVER, TIMO

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20101105

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130903